» Articles » PMID: 38994977

The Influence of Metabolic Risk Factors on the Inflammatory Response Triggered by Myocardial Infarction: Bridging Pathophysiology to Treatment

Overview
Journal Cells
Publisher MDPI
Date 2024 Jul 12
PMID 38994977
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial infarction (MI) sets off a complex inflammatory cascade that is crucial for effective cardiac healing and scar formation. Yet, if this response becomes excessive or uncontrolled, it can lead to cardiovascular complications. This review aims to provide a comprehensive overview of the tightly regulated local inflammatory response triggered in the early post-MI phase involving cardiomyocytes, (myo)fibroblasts, endothelial cells, and infiltrating immune cells. Next, we explore how the bone marrow and extramedullary hematopoiesis (such as in the spleen) contribute to sustaining immune cell supply at a cardiac level. Lastly, we discuss recent findings on how metabolic cardiovascular risk factors, including hypercholesterolemia, hypertriglyceridemia, diabetes, and hypertension, disrupt this immunological response and explore the potential modulatory effects of lifestyle habits and pharmacological interventions. Understanding how different metabolic risk factors influence the inflammatory response triggered by MI and unraveling the underlying molecular and cellular mechanisms may pave the way for developing personalized therapeutic approaches based on the patient's metabolic profile. Similarly, delving deeper into the impact of lifestyle modifications on the inflammatory response post-MI is crucial. These insights may enable the adoption of more effective strategies to manage post-MI inflammation and improve cardiovascular health outcomes in a holistic manner.

Citing Articles

The spleen in ischaemic heart disease.

Heusch G, Kleinbongard P Nat Rev Cardiol. 2025; .

PMID: 39743566 DOI: 10.1038/s41569-024-01114-x.


The Role of Inflammation in the Pathogenesis of Cardiogenic Shock Secondary to Acute Myocardial Infarction: A Narrative Review.

Kologrivova I, Kercheva M, Panteleev O, Ryabov V Biomedicines. 2024; 12(9).

PMID: 39335587 PMC: 11428626. DOI: 10.3390/biomedicines12092073.

References
1.
Zhao J, Yang Y, You S, Cui C, Gao R . Different effects of postconditioning on myocardial no-reflow in the normal and hypercholesterolemic mini-swines. Microvasc Res. 2006; 73(2):137-42. DOI: 10.1016/j.mvr.2006.09.002. View

2.
Salari N, Morddarvanjoghi F, Abdolmaleki A, Rasoulpoor S, Khaleghi A, Afshar Hezarkhani L . The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023; 23(1):206. PMC: 10122825. DOI: 10.1186/s12872-023-03231-w. View

3.
Haas M, Alicot E, Schuerpf F, Chiu I, Li J, Moore F . Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc Res. 2010; 87(4):618-27. PMC: 2920809. DOI: 10.1093/cvr/cvq141. View

4.
Liao Y, Cheng X . Autoimmunity in myocardial infarction. Int J Cardiol. 2006; 112(1):21-6. DOI: 10.1016/j.ijcard.2006.05.009. View

5.
Andreadou I, Schulz R, Badimon L, Adameova A, Kleinbongard P, Lecour S . Hyperlipidaemia and cardioprotection: Animal models for translational studies. Br J Pharmacol. 2019; 177(23):5287-5311. PMC: 7680007. DOI: 10.1111/bph.14931. View